<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(40)</volume><submitter>Song Y</submitter><pubmed_abstract>Selective elimination of senescent cells (senolysis) has become a promising therapeutic strategy for the management of chronic renal failure (CRF), but the senolytic molecular pathways towards CRF therapy are limited. Here, we present for the first time a senescence-associated β-galactosidase (SA-β-gal) activatable theragnostic prodrug strategy to pertinently and effectively treat CRF in mice with the aid of fluorescence-guided senolysis. The signs of premature senescence, including the overexpression of β-gal, have been found in kidneys of mice with CRF, making this enzyme particularly suitable as a trigger of prodrugs for CRF therapy. With this unique design, our pioneering prodrug TSPD achieved the activation of a fluorophore for tracking and the specific release of the parent drug, gem</pubmed_abstract><journal>Chemical science</journal><pagination>11738-11745</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9580481</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A senolysis-based theragnostic prodrug strategy towards chronic renal failure.</pubmed_title><pmcid>PMC9580481</pmcid><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Qiao S</pubmed_authors><pubmed_authors>Guo Y</pubmed_authors><pubmed_authors>Sun T</pubmed_authors><pubmed_authors>Shi D</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Song Y</pubmed_authors><pubmed_authors>Liu W</pubmed_authors></additional><is_claimable>false</is_claimable><name>A senolysis-based theragnostic prodrug strategy towards chronic renal failure.</name><description>Selective elimination of senescent cells (senolysis) has become a promising therapeutic strategy for the management of chronic renal failure (CRF), but the senolytic molecular pathways towards CRF therapy are limited. Here, we present for the first time a senescence-associated β-galactosidase (SA-β-gal) activatable theragnostic prodrug strategy to pertinently and effectively treat CRF in mice with the aid of fluorescence-guided senolysis. The signs of premature senescence, including the overexpression of β-gal, have been found in kidneys of mice with CRF, making this enzyme particularly suitable as a trigger of prodrugs for CRF therapy. With this unique design, our pioneering prodrug TSPD achieved the activation of a fluorophore for tracking and the specific release of the parent drug, gem</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2025-04-05T13:27:42.683Z</modification><creation>2025-04-05T13:27:42.683Z</creation></dates><accession>S-EPMC9580481</accession><cross_references><pubmed>36320912</pubmed><doi>10.1039/d2sc03525a</doi></cross_references></HashMap>